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intestinal microbiota may contribute to progression of chronic
liver damage, especially liver ﬁbrogenesis [8], which in turn
may aggravate not only installed cirrhotic lesions through
increased inﬂammation and ﬁbrosis, but also accelerate or
provoke progression of NASH and alcoholic steatohepatitis to
cirrhosis. Thus, the role, in humans, of BT in the progression of
chronic hepatic damage, both in installed cirrhosis and precirrh-
otic lesions, may appear of paramount importance, in conjunction
with persistent alcohol consumption in cases of alcoholic chronic
liver disease and cirrhosis. There is increasing suggestive evi-
dence that bacterial translocation and intestinal ﬂora dysfunction
are associated with the development of liver ﬁbrosis [9], and that
bacteria and microbial products, including endotoxins – like
lipopolysaccharides (LPS) macromolecules, the major molecular
component of the outer membrane of Gram-negative bacteria –,
bacterial DNA or microbial metabolites – like ethanol produced
by the intestinal microbiome or choline – may contribute to the
pathogenesis of NAFLD and NASH, and presumably to progression
to overt cirrhosis due to increased ﬁbrogenesis [6]. Finally, this
clearly suggests the possible associated role of chronic, repetitive
BT, not only in mesenteric lymph nodes but also in portal blood
and the liver itself [10], as elicited by a chronically leaky intestine
(which may precede and/or be the consequence of cirrhosis and
be aggravated – in alcohol-induced chronic liver disease – by per-
sistent chronic alcohol consumption), in cirrhosis pathogenesis
itself.
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Open access undReply to: ‘‘Bacterial translocation in liver cirrhosis: Site
and role in ﬁbrogenesis’’To the Editor:
We greatly appreciate the comments raised by Dr Matuchansky
regarding our recent review on pathological bacterial transloca-
tion (BT) in liver cirrhosis [1]. As for the site of BT in cirrhosis
we acknowledge the investigation in compensated cirrhotic
patients utilizing a multisugar test [2]. The study described by
Dr Matuchansky reports in cirrhotic individuals an increased
sucralose/erythritol ratio in 5–24 h urine (supposed to indicate
colonic permeability) whereas the lactulose/rhamnose ratio in
0–5 h urine (supposed to represent small intestinal permeability)
was not altered. This study has not been cited by us due to (i) the
fact, that any information gained by using sugar tests most likely
does not reﬂect permeability to macromolecules such as bacteria
and/or bacterial cell wall components, (ii) criticisms related to
methodological issues in performance of those sugar tests
[3–5], and ﬁnally (iii) the limitation in references to be used.Journal of Hepatology 20
er CC BY-NC-ND license.Sugars utilized in those permeability tests are very small mole-
cules (182–400 Da) whose passage across the mucosal barrier is
not necessarily related to structural damage in the tight junction
barrier that permits increased penetration of large molecules
(e.g., lipopolysaccharide can reach up to 100,000 Da). Moreover,
although not convincingly proven at least for living bacteria, like-
wise larger in size than mono-/disaccharides, BT occurs most
likely via transcytosis (Fig. 1). Transcytosis of vital bacteria how-
ever is complex, includes active sampling by dendritic cells and
transport across M cells as well as epithelial cells all of which is
regulated different from transport of sugars in terms of initiation,
kinetics and host response. Therefore, also others have proposed
that measuring permeability to small sugar molecules does not
correlate with gut dysbiosis, endotoxin release, microbial translo-
cation and/or activation of the mucosal immune system [6,7].
Mucosal defense mechanisms (e.g., number and secretion of14 vol. 61 j 706–716
goblet cells, concentration of antimicrobial peptides) gradually
increase along the GI-tract similar to the increasing numbers of
microbial organisms present encompassing sufﬁcient ﬁrewalls
combating the local microbiota. In contrast, number of dendritic
cell (DC)-extensions into the intestinal lumen is highest in the
proximal small intestine and lowest in the terminal ileum [8]
emphasizing the highest degree of host-microbial interaction at
the site with the least bacterial load enabling ﬁne-tuning of
immune responses at different levels. Therefore, we strongly
believe that more research should focus on defence mechanisms
and immunological responses to BT within the small intestine in
liver cirrhosis.
We completely agree with the second point raised by
Dr Matuchansky that the microbiome has a major role in hepatol-
ogy, and it goes beyond the impact on bacterial infections and/or
other complications in liver cirrhosis. In fact, its pathophysiolog-
ical impact on liver injury, ﬁbrogenesis and inﬂammation is just
starting to be unravelled. However, this was clearly beyond the
scope of our review that intended solely to focus on pathological
BT in fully established liver cirrhosis and not pre-cirrhotic, ﬁbro-
tic stages of liver disease and/or conditions of non-alcoholic fatty
liver disease (NAFLD)/-steatohepatitis (NASH). In addition, to
what has elegantly been summarized we would like to present
a modiﬁed ﬁgure previously published by one of us (Fig. 2). In
addition to the role of inﬂammasomes and effects of pathogen-
associated-molecular-patterns (PAMPs) intrahepatically in rela-
tion to the colonic microbiota and progression of NASH there
are multiple other actions initiated and/or modulated by
gut-derived PAMPs on basically any cell type present within
the liver. These include but are not limited to synthesis and
release of pro-, anti-inﬂammatory cytokines, chemokines, growth
factors, reactive-oxygen species etc. and alteration of diverse
intracellular signaling cascades of which much has to be unrav-
elled in the future.
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Fig. 1. Electron microscopic image of rat ileum from healthy (B) and cirrhotic
rats (A and C). (A) Arrows indicate widening and edema of the intercellular space.
Moreover, strong loss of microvilli and adherence of bacteria to the epithelial
surface can be appreciated but no bacteria neither intracellular nor in the
intercellular space; (C) in contrast, here multiple bacteria are located within the
epithelial cell just above the basolateral membrane evidencing transcellular route
of crossing the epithelium. MV, microvilli; PM, plasma membrane; ZO, zonula
occludens; ZA, zonula adherence; D, desmosome; C, cell; ⁄bacteria. (This ﬁgure
appears in colour on the web.)
Fig. 2. Hypothetical scheme on impact of bacteria/wall components in the
liver (modiﬁed after [9]). (This ﬁgure appears in colour on the web.)
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